Profilaxis preexposición (PrEP) frente al VIH: eficacia, seguridad e incertidumbres

Matilde Sanchez Conde; María Jesús Vivancos Gallego; Santiago Moreno Guillen

doi:10.7399/fh.10821

Profilaxis preexposición (PrEP) frente al VIH: eficacia, seguridad e incertidumbres

Matilde Sanchez Conde, María Jesús Vivancos Gallego, Santiago Moreno Guillen

Resumen

En los últimos años se ha objetivado un incremento de las nuevas infecciones por el VIH en el grupo de hombres que tienen sexo con hombres, lo que indica la ausencia de eficacia de las campañas y medidas preventivas instauradas en dicho grupo.
Es necesario, por tanto, implementar medidas preventivas alternativas, siendo la profilaxis farmacológica pre-exposición (PrEP) una de las opciones mejor evaluadas tanto en ensayos clínicos como en la vida real, habiéndose demostrado tasas de protección superiores al 80% cuando se administra en los casos indicados y con buen cumplimiento terapeútico.
La estrategia ha demostrado, además, un perfil adecuado en seguridad,
tolerancia y efectos adversos, siendo además coste-efectiva según los
estudios realizados para valorar este importante aspecto.

Palabras clave

Profilaxis preexposición; Infección por el VIH; Eficacia

Texto completo:

PDF (English)

Referencias

Singh S, Song R, Johnson AS, McCray E, Hall I. HIV incidence, prevalence, and undiagnosed infections in men who have sex with men. | CROI Conference. Retroconference Retroviruses Opportunistic Infect Febr 13-17, 2017 Seattle [cited 2017 Apr 27]; Available from: http://www.croiconference.org/sessions/hiv-incidenceprevalence-and-undiagnosed-infections-men-who-have-sex-men

Vigilancia Epidemiológica del VIH y SIDA en España. [Informe en internet]. Dirección general de Salud Pública, Calidad e Innovación 2016. (citado mayo 2017) Disponible en: https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/InformeVIH_SIDA_2016.pdf

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med. 2010;363:2587–99.

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2012;367:423–34.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med. 2012;367:399–410.

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open- label randomised trial. Lancet. 2016 ;387:53–60.

Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237–46.

Sivay M V, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, et al. Characterization of HIV seroconverters in a TDF/FTC PrEP study. JAIDS J Acquir Immune Defic Syndr [Internet]. 2017 Mar 22 [cited 2017 Apr 27];1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28328548

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med. 2012;367:411–22.

Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med. 2015;372:509–18.

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.

Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection. Sci Transl Med. 2010;2(14):14ra4.

Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014 Clinical Practice Guideline Preexposure prophylaxis for the prevention of HIV infection in the United States -2014. [cited 2017 Apr 27]; Available from: https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf

Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis. 2015;61:1601–3.

Liu A, Cohen S, Vittinghoff E. Adherence, Sexual Behavior and HIV/STI Incidence Among MSM and Transgender Women in the US PrEP Demo Project. 8th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Julio 2015. Vancouver, Canada. Abstract TUAC0202.

Hosek S, Rudy B, Landovitz R. ATN 110: An HIV PrEP Demonstration Project and Safety Study for Young Men who Have Sex with Men in the United States. 8th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Julio 2015. Vancouver, Canada. Abstract TUAC0204LB.

Whitlock G, Patel S, Suchak T. Rapid initiation of antiretroviral treatment in newly diagnosed HIV: experience of a central London clinic. 23rd Annual Conference of the British HIV Association. Liverpool, April 4- 7, 2017. Abstract O14.

Delpech V. Towards elimination of HIV amongst gay and bisexual men in the United Kingdom. 23rd Annual Conference of the British HIV Association. Liverpool, April 4-7, 2017.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, et al. Changes in Glomerular Kidney Function Among HIV-1 – Uninfected Men and Women Receiving Emtricitabine – Tenofovir Disoproxil Fumarate Preexposure Prophylaxis. JAMA Intern Med. 2015;175:246.

Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, et al. Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis with Tenofovir- Emtricitabine or Placebo in Botswana. Lama JR, editor. PLoS One. 2014;9:e90111.

Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink H-J, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151– 8.

Knox DC, Anderson PL, Harrigan PR, Tan DHS. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. N Engl J Med. 2017;376:501–2.

Landovitz RJ. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation. Top Antivir Med. 2017;23:85–90.

Parikh UM, Mellors JW. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Curr Opin HIV AIDS. 2016;11:49–55.

Dimitrov DT, Boily M-C, Hallett TB, Albert J, Boucher C, Mellors JW, et al. How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact. Apetrei C, editor. PLoS One. 2016;11(7):e0158620.

Elske H, Godelieve J de B. Acute infection with a wild- type HIV-1 virus in prep user with high TDF levels.. CROI Conf Febr 13-16, 2017 Seattle, Washington Abstr 953; Available from: http://www.croiconference.org/sessions/acute-infection-wild-typehiv-1-virus-prep-user-high-tdf-levels

Harawa NT, Holloway IW, Leibowitz A, Weiss R, Gildner J, Landovitz RJ, et al. Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition. AIDS. 2017 31:739–40.

DOI: http://dx.doi.org/10.7399%2Ffh.10821